Duloxetine Capsule, Delayed Release
Product Images NDC 71610-957

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-957). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0957 74)

This is a description of a medication named "Duloxetine DR USP" in capsule form. The package contains 500 capsules with a National Drug Code (NDC) number of 7161095774. The batch number is mentioned as 1, and the expiration date is not specified in the provided text.*

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

The text provides data on the proportion of patients with relapse over time for a study comparing placebo with duloxetine treatment. The graph shows the time from randomization to relapse in days, using the Kaplan-Meier estimator method.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

This data table showcases the proportion of patients experiencing a relapse over time for both the placebo and duloxetine treatments. The graph on the right side illustrates how the relapse rates evolve with time from randomization. The Kaplan-Meier estimator method was utilized for calculating the relapse percentages.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

This text provides information on the percentage of patients improved with different doses of duloxetine and a placebo. It also mentions the percent improvement in pain from baseline. It seems to be part of a medical or research document evaluating the effectiveness of duloxetine in treating pain.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

This text describes the percentage of patients who showed improvement in pain from baseline after taking different treatments - Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The text does not provide specific data on the percentage of improvement for each treatment.*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

Percentage of patients improved in pain from baseline for different dosages of Duloxetine compared to placebo. The chart shows different levels of percent improvement in pain for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

Percentage of Patients Improved can be evaluated based on the chart provided. The chart displays the comparison between patients taking Duloxetine at different dosages and a placebo. The percentage improvements in pain from baseline are shown for each group: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 60 mg once daily, and Placebo. The percentages range from 0 to 100, indicating the level of pain improvement experienced by the patients in each group.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

This is a description of the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. The study compares the pain relief effects of Duloxetine 60mg once daily versus a placebo. Duloxetine-treated patients started with 30mg once daily for 1 week, increasing to 60mg once daily for 12 weeks. The pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

Percentage of Patients Improved: 100% Placebo, 60/120 mg duloxetine once daily. Percent Improvement in Pain from Baseline (BOCF).*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

This information provides data on the percentage of patients who showed improvement in pain levels after being treated with a placebo versus duloxetine 60 mg. The graph indicates a gradual increase in the percentage over time, with duloxetine showing a higher improvement rate compared to the placebo. The values suggest a significant impact of duloxetine in reducing pain levels from the baseline.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

This text provides information on the percentage of patients improved with Duloxetine 60/120 mg compared to a placebo. It shows a graph representing the percent improvement in pain from baseline. The data suggests that there is a significant improvement in patients taking Duloxetine compared to a placebo in terms of pain relief.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

FDA Label Image

Aphena (Aphena)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.